Innovative
Cachexia Treatment

Pephexia Therapeutics is a biotechnology company working with the discovery and development of novel peptide-based pharmacotherapies for an effective and convenient treatment of cachexia, sarcopenia, and related diseases.

FOCUS AREA

Cachexia is a severe and growing wasting disease that affects around 9 million patients and causes a total of 1.5-2.0 million deaths per year1.

Cachexia is defined as un-intended weight loss of a least 5% in 12 months or less. A range of underlying diseases can cause cachexia, most commonly chronic obstructive pulmonary disease (COPD), cancer, congestive heart failure, chronic kidney disease, and rheumatoid arthritis2. In cancer cachexia accounts for 20% of the deaths3, and in COPD cachexia is associated with 50% reduction in median survival4. Cachexia patients often experience a loss of appetite and a loss of muscle tissue and strength leading to fatigue, and an overall lowered quality of life2. Moreover, cachexia is associated with an abnormal metabolism with a range of immune, neurohormonal, and biochemical abnormalities associated with the underlying pathologies and a negative energy balance. Treatment of cachexia includes nutritional supplementation, however there is still a large unmet medical need for novel and efficacious pharmacotherapies to improve the quality of life of these patients.

References:
1Von Haehling et al. (2016) JCSM 7 (5), 507-509; 2Eldrige and Dorg (2019) Verywellhealth; 3Fortune Business Insights: Cancer cachexia – pipeline review 2019; 4Wagner et al. (2008) Eur Respir J 31, 492-501.

9000000
PATIENTS AFFECTED
1500000
DEATHS PER YEAR
MISSON

We aim to deliver a novel, innovative, and effective pharmacotherapy for the treatment of cachexia based on naturally occuring peptide hormones.

TEAM

Board of Directors
Management and advisors
Scientific Advisory Board

NEWS

A few facts about cachexia

The major underlying diseases of cachexia are COPD, Cancer and Congestive Heart Failure1. As an example up to 40% of patients with COPD experience muscle wasting2.

1Von Haehling et al. (2016) JCSM 7 (5), 507-509; 2Sanders et al (2016) JCSM 7 (1), 5-22.

Cachexia in cancer is responsible for around 20% deaths among cancer patients globally3.

3Fortune Business Insights: Cancer cachexia – pipeline review 2019.

Cachexia in COPD is associated with 50% reduction in median survival4.

4Wagner et al. (2008) Eur Respir J 31, 492-501.

CONTACT

Pephexia Therapeutics ApS
VAT number 41319208

Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark

kfo@pephexia.com

+45 50 91 09 69